inquiry@market.us
+1 718 874 1545 (International)
+91 78878 22626 (Asia)
Search...
All Reports
All Sectors
Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Multiple Sclerosis Drugs Market
Global Multiple Sclerosis Drugs Market By Type (Immunomodulators, Interferons,
Immunosuppressants), Route Of Administration (Oral, Parenteral), Distribution Channel
(Hospital Pharmacy, Online Pharmacy) By Region and Companies - Industry Segment
Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
Published date: Nov 2023
Report ID: 51496
Number of Pages: 215
Inquiry Before Buying
Mention interested topics/company
Format:
profiles.
Overview
Table of Contents
Major Market Players
Request a Free Sample
Enter Name
Enter Email ID
Quick Navigation
-Select Country-
Report Overview
Enter Phone Number
The Global Multiple Sclerosis Drugs Market size is expected to be worth around USD 41 Billion by
Enter Company Name
2032 from USD 28.2 Billion in 2022, growing at a CAGR of 3.8% during the forecast period from 2022 to
2032.
Submit
A chronic inflammatory immune-mediated disease called multiple sclerosis (MS) damages the nerve cells
in the spinal cord and brain by producing neurodegeneration, demyelination, and axonal transection. Some
of the most often used treatments include muscle relaxants, antidepressants, oral, injectable, infused
medicines, physical therapy, and others.
oral drugs such as Teriflunomide, Cladribine, and Dimethyl fumarate are highly used in the treatment of
multiple sclerosis. Intravenous infusion therapies such as Ocrelizumab, Alemtuzumab, and Natalizumab &
injectable therapies such as Interferon-Beta and Glatiramer Acetate are administered into the muscle and
derive fast results.
Report ID
51496
Published Date
Nov 2023
Rating
★ ★ ★ ★ ★ (27)
Buy
add_shopping_cart Now
Trusted by more than 17382
organizations globally
*Actual Numbers Might Vary In The Final Report
Key Takeaways
Global Sales Projection: The multiple sclerosis drugs market sales are expected to reach US$ 41
Billion by 2033.
Growth Rate: The market is predicted to grow at a CAGR of 3.8% from 2023 to 2032.
Recent Market Value: The market was worth US$ 28.2 Billion in 2022.
MS Treatments: Treatments include oral drugs, injectables, antidepressants, muscle relaxants, and
infused medicines.
Key Drug Type: There’s a high demand for the Immunosuppressant segment.
Main Way of Taking Drugs: By route of administration, the oral segment had the largest market
share.
Primary Sellers: The hospital pharmacy segment holds the largest share in distribution channels
globally.
Regional Shares:
– In 2022, North America had the highest revenue share of 43.1%.
– Europe accounted for a 28% revenue share in 2022.
MS Varieties: Multiple sclerosis has four types – secondary-progressive, primary-progressive,
relapsing-remitting, and progressive-relapsing.
Healthcare Spending: Rising expenditure on healthcare is a major driver for the growth of the
multiple sclerosis drugs market.
Market Challenges: The costly treatment can be a hurdle, as might issues like qualified worker
shortages in developing nations.
Research Activities: An increase in R&D activities is a major push for market growth.
New Technologies: Investments in new tech for the MS drugs market are on the rise.
Awareness Efforts: Campaigns raising awareness about multiple sclerosis treatments are leading
to an increase in demand for these drugs.
Type Analysis
The Immunosuppressant Market Segmentation Accounted for the Largest Share of Multiple
Sclerosis Drugs Market
Based on types, the global multiple sclerosis drugs market is segmented into immunomodulators,
interferons, immunosuppressants, and others. among these types, the largest market share was occupied
by immunosuppressants. because they help patients with relapsing-remitting multiple sclerosis (RRMS) by
weakening the immune system, which in turn suppresses the body’s autoimmune onslaught and prevents
relapses.
additionally, it is projected that a rise in product approvals for MS medicines will fuel market expansion on a
global scale. currently, the immunosuppressants such as alemtuzumab, ocrelizumab, glatiramer Acetate,
dimethyl fumarate, natalizumab, fingolimod, interferon beta preparations, and teriflunomide have been
authorized for use exclusively in relapse forms of MS.
Route of Administration Analysis
The Oral Segment Accounted for the Largest Share of the Multiple Sclerosis Drugs Market
Based on the route of administration analysis, the global multiple sclerosis drugs market is segmented into
injectable, Oral, and Intravenous. Among these routes of administration segment, the largest market share
was occupied by oral. Because the oral mode of delivery boosts therapeutic compliance and fosters patient
satisfaction. The market is expected to develop as a result of significant therapeutic advancements in the
novel oral medications licensed for the therapeutics of MS.
Regulating bodies have approved Fingolimod, Dimethyl Fumarate, and Teriflunomide as three oral
segment medications for the treatment of multiple sclerosis. The mechanisms, efficiency, and safety from
these medications, which have produced encouraging findings during phase III clinical trials, are important
factors in the global expansion of the industry.
Distribution Channel Analysis
The Hospital Pharmacy Segment Accounted for the Largest Market Share in Multiple Sclerosis
Drugs Market
Based on distribution channel analysis, the global multiple sclerosis drugs market is segmented into
hospital pharmacies, online Pharmacies, retail Pharmacies, and others. Among these distribution channel
segments, the largest share was occupied by hospital pharmacies due to favorable health reimbursement
and increased government initiatives to enhance the government hospital pharmacies.
Additionally, with more online portals selling prescription medications around the world, the online
pharmacy market is set to grow profitably. Additionally, in response to the COVID-19 outbreak, lockdown
limitations were implemented globally to stop the virus’s propagation. As a result, there was a greater
demand for medication home delivery, which fueled the segment’s expansion.
Key Market Segments
By Type
Immunomodulators
Interferons
Immunosuppressants
Other types
Route of Administration
Oral
Parenteral
Others
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other Distribution Channels
Drivers
Increasing Multiple Sclerosis Prevalence Drive the Multiple Sclerosis Drugs Market
The multiple sclerosis drugs market is expanding mostly due to the high disease growing incidence.
Multiple sclerosis comes in four different forms such as relapsing-remitting, primary-progressive,
secondary-progressive, and progressive-relapsing. During the forecast period, the market dynamics will be
impacted by these types of high prevalence growth rates.
Improving Healthcare Infrastructure Investment boosts the Multiple Sclerosis market revenue
The increasing expenditure on healthcare contributes to the development of the market for multiple
sclerosis and it is a crucial element in determining its growth rate in the forecast period. The market for
multiple sclerosis will also grow as more public and private groups and will launch awareness-raising
campaigns with increasing market penetration.
Hence, the multiple sclerosis market will also grow as a result of increasing disposable income and the
acceleration of the discovery of novel monoclonal antibodies, immunomodulators, immunosuppressants,
and interferons. In addition to this, a growing elderly population and a constantly evolving way of life will
accelerate the sclerosis drugs market growth.
Restraints
Difficulties Due to a Shortage of Qualified Workers and a Shortage of Healthcare Systems in
Emerging Nations
The expensive nature of treating multiple sclerosis may slow down the expansion of the market in the
forecast period. The market for multiple sclerosis will face difficulties due to a shortage of qualified workers
and a shortage of healthcare systems in emerging nations. Additionally, a decrease in patient visits brought
on by the COVID-19 epidemic and an absence of public awareness may constrain and hamper the
market’s growth rate in the forecast period.
Opportunity
A Rise in the Amount of R&D Activity
A rise in the quantity of R&D activities is a major factor driving the market’s expansion in the forecast
period. This will present advantageous chances for the expansion of the multiple sclerosis market. In
addition to this, a rise in drug releases and clearances will speed up the market’s expansion. During the
projected period, increased investments in the creation of cutting-edge technologies and an expansion in
the number of new markets will also present market opportunities for multiple sclerosis market expansion.
Regional Analysis
North America Held the Highest Share of the Global Multiple Sclerosis Market
Due to a rise in the need for multiple sclerosis therapeutic items, North America held the highest
percentage of the global market for multiple sclerosis therapeutics in 2022. Easy access to multiple
sclerosis medications and improved favorable government reimbursement policies for multiple sclerosis
therapy are other factors that support the market growth for multiple sclerosis medicines in North America.
Additionally, the industry is growing since major companies like Novartis, Pfizer, and Bayer are present in
the area. Additionally, it’s been discovered that multiple sclerosis prevalence is higher in areas farthest
from the equator; as a result, multiple sclerosis prevalence in North America is frighteningly high.
Infrastructure Expansion and the High Prevalence of Unmet Demands Are Projected to
Promote Growth in the Asia Pacific
The market in Asia Pacific is the most profitable, with many potential areas for future expansion.
Infrastructure expansion and the high prevalence of unmet demands are projected to promote growth over
the projection period. Prominent players are getting into relationships with regional market medicine
makers in an effort to take advantage of this growing potential.
Key Regions
North America
The US
Canada
Mexico
Western Europe
Germany
France
The UK
Spain
Italy
Portugal
Ireland
Austria
Switzerland
Benelux
Nordic
Rest of Western Europe
Eastern Europe
Russia
Poland
The Czech Republic
Greece
Rest of Eastern Europe
APAC
China
Japan
South Korea
India
Australia & New Zealand
Indonesia
Malaysia
Philippines
Singapore
Thailand
Vietnam
Rest of APAC
Latin America
Brazil
Colombia
Chile
Argentina
Costa Rica
Rest of Latin America
Middle East & Africa
Algeria
Egypt
Israel
Kuwait
Nigeria
Saudi Arabia
South Africa
Turkey
United Arab Emirates
Rest of MEA
Key Market Players Analysis
Market players are subject to intense competition from top market players, particularly those with strong
brand recognition and high distribution networks like Novartis, Pfizer Inc., and Bayer.
To stay on top of the market, companies have gained various expansion strategies such as partnerships
and product launches such as Tecfidera was released by Biogen Idec.
Market Key Players
Celgene Corporation
Abbvie Inc.
Acorda Therapeutics Inc.
Actelion Pharmaceuticals (Johnson & Johnson)
Adamas Pharmaceuticals Inc
Bayer AG
Biogen Inc.
Cipla Inc.
Eli Lilly and Company
EMD Serono (Merck KGaA)
Pfizer Inc.
Sanofi
Teva Pharmaceuticals Industries Ltd.
Novartis AG.
Bristol-Myers Squibb Company
Hoffmann-La Roche Ltd.
Other Key Players
Recent Development
On June 22, 2022, Biogen and Happify Health announced their partnership to support and brace
patients with Multiple Sclerosis on the online platform. Through this partnership, the company hopes
to support multiple sclerosis patients’ care and treatment journeys, promote holistic health objectives,
offer professional advice, and help build a supportive network.
On July 25, 2022, The U.S. FDA granted natalizumab, the first biosimilar drug created by
Polypharma Biologics, approval. The drug is approved for a number of conditions, including relapse
multiple sclerosis and relapse-remit multiple sclerosis. The European Medicines Agency (EMA) has
also approved the marketing authorization application (MAA) for this potential biosimilar.
Report Scope
Report Features
Description
Market Value (2022)
USD 28.2 Billion
Forecast Revenue (2032)
USD 41 Billion
CAGR (2023-2032)
3.8%
Base Year for Estimation
2022
Historic Period
2016-2021
Forecast Period
2023-2032
Report Coverage
Revenue Forecast, Market Dynamics, Competitive Landscape, Recent
Developments
Segments Covered
By Type (Immunomodulators, Interferons, Immunosuppressants, and Others),
Route of Administration (Oral, Parenteral, Others), Distribution Channel
(Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, and Others)
Regional Analysis
North America – The US, Canada, & Mexico; Western Europe – Germany,
France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux,
Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The
Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan,
South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines,
Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil,
Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East &
Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa,
Turkey, United Arab Emirates, & Rest of MEA
Competitive Landscape
Celgene Corporation, Abbvie Inc., Acorda Therapeutics Inc., Actelion
Pharmaceuticals (Johnson & Johnson), Adamas Pharmaceuticals Inc, Bayer
AG, Biogen Inc., Cipla Inc., Eli Lilly and Company, EMD Serono (Merck KGaA),
Pfizer Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Novartis AG., BristolMyers Squibb Company, F. Hoffmann-La Roche Ltd., Other Key Players
Customization Scope
Customization for segments, region/country-level will be provided. Moreover,
additional customization can be done based on the requirements.
Purchase Options
We have three licenses to opt for: Single User License, Multi-User License (Up
to 5 Users), Corporate Use License (Unlimited User and Printable PDF)
Frequently Asked Questions (FAQ)
What was the Market Segmentation of the Multiple Sclerosis Drugs Market?
By Type (Immunomodulators, Interferons, Immunosuppressants, and Others), Route of
Administration (Oral, Parenteral, Others), Distribution Channel (Hospital Pharmacy, Online
Pharmacy, Retail Pharmacy, and Others)
What is the CAGR of Multiple Sclerosis Drugs Market?
The Multiple Sclerosis Drugs Marketis growing at a CAGR of 3.8% during the forecast period
2023 to 2033.
Who are the major players operating in the Multiple Sclerosis Drugs Market?
Celgene Corporation, Abbvie Inc., Acorda Therapeutics Inc., Actelion Pharmaceuticals (Johnson
& Johnson), Adamas Pharmaceuticals Inc, Bayer AG, Biogen Inc., Cipla Inc., Eli Lilly and
Company, EMD Serono (Merck KGaA), Pfizer Inc., Sanofi, Teva Pharmaceuticals Industries Ltd.,
Novartis AG., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Other Key Players
Which region will lead the Global Multiple Sclerosis Drugs Market?
North America is estimated to be the fastest-growing region during the forthcoming years.
Multiple Sclerosis Drugs Market
Published date: Nov 2023
add_shopping_cart Buy Now
get_app Download Sample
Related Reports
Pharmaceutical Cartridges Market
Infertility Drugs Market
Generic Pharmaceuticals Market
Dermatophytic Onychomycosis Treatment Market
Atopic Dermatitis Drugs Market
Myelodysplastic Syndrome Drugs Market
Our Clients
SINGLE USER
MULTI USER
$6,000
$8,000
CORPORATE USER
$10,000
$3,999
$5,999
$6,999
USD / PER UNIT
USD / PER UNIT
USD / PER UNIT
SAVE 24%
SAVE 28%
SAVE 32%
No
up to 10 hrs work
up to 30 hrs work
1 User
2-5 User
Unlimited
up to 20 hrs
up to 40 hrs
up to 50 hrs
Up to 20% off on next purchase
Up to 25% off on next purchase
Up to 30% off on next purchase
Buy Now ($ 3,999)
Buy Now ($ 5,999)
Buy Now ($ 6,999)
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization
Accessibility
Analyst Support
Benefit
Lexington
location_on 420
Avenue, Suite 300
New York City, NY
10170,
United States
718 874 1545
phone +1
(International)
phone +91 78878 22626 (Asia)
Find Help
Explore
Contact Us
About Us
How to Order
All Reports
Legal
All Sectors
Secured Payment Options
email inquiry@market.us
Privacy Policy
Infographics
Refund Policy
Statistics and Facts
Frequently Asked Questions
Companies
Terms and Conditions
© 2025 Market.Us. All Rights Reserved.